Our main strategic goals are to be a solid Speciality Pharmaceutcal Company in Spain by enhancing technology transfer and increasing export activity in order to boost our international presence.

R&D is a cornerstone of the company's mission and growth strategy. This activity is focused on finding new and innovative technologies to develop pharmaceutical forms with added-value for patients in our different areas of expertise.

Rubió’s goal is to provide the pharmaceutical market with the best quality products. Examples of this philosophy are the pioneer introduction on methylphenidate (Rubifen) for the treatment of Attention Deficit Hyperactivity Disorder, phosphate binding molecules (Royen) and the cation exchange resins (Resincalcio and Resindosio) to treat patients with chronic renal failure.

Our R&D team works according to International Conference for Armonization (ICH) standards and under Good Clinical Practice (GCP), Good Laboratory Practice (GLP) and Standards Good Manufacturing Practice (GMP).

Laboratorios Rubió’s scientists have established collaborations with research groups, external scientists, universities, hospitals and internationally recognized technology companies. These synergies take place in different countries worldwide. Moreover, our company has an important network of specialised international consultants.

In order to be permanently updated with the relevant information within the areas of interest, our team attends different scientific congresses regularly.